Literature DB >> 19476012

Nonimmediate allergic reactions induced by drugs: pathogenesis and diagnostic tests.

M J Torres1, C Mayorga, M Blanca.   

Abstract

Nonimmediate allergic reactions (NIRs) to drugs, which are the most common reactions induced by specific immunologic mechanisms, can be induced by all commercially available drugs. NIRs can appear hours, days, or even weeks after drug intake. They elicit a spectrum of manifestations, mostly affecting the skin, ranging from maculopapular exanthema and urticaria to other less common but more severe entities such as acute generalized exanthematic pustulosis, drug rash with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome, Stevens-Johnson syndrome, and toxic epidermal necrolysis. The main pathologic event involved in NIRs is a T-cell effector response and the wide heterogeneity of clinical symptoms may reflect differences in the underlying immunologic mechanisms. Despite their clinical heterogeneity, NIRs share certain aspects such as the activation of T cells with increased expression of CD25 and HLA-DR. NIRs are classified as type 1 helper (T(H)1) T-cell responses, characterized by the production of interferon-gamma, tumor necrosis factor-alpha, interleukin 2, T-bet, and the cytotoxic markers perforin and granzyme B. Diagnosis is often complicated because of the difficulty of obtaining a reliable clinical history, the important role played by cofactors such as viral diseases, and the low sensitivity of skin tests and in vitro tests. Further studies are thus required in order to improve our understanding of NIRs and refine our diagnostic criteria.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19476012

Source DB:  PubMed          Journal:  J Investig Allergol Clin Immunol        ISSN: 1018-9068            Impact factor:   4.333


  18 in total

Review 1.  Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to 'de-labeling'.

Authors:  Jason Trubiano; Elizabeth Phillips
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

Review 2.  Delayed drug hypersensitivity: models of T-cell stimulation.

Authors:  Jacqueline Adam; Werner J Pichler; Daniel Yerly
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

Review 3.  Oral bullous eruption after taking lisinopril--case report and literature review.

Authors:  Marinka Baričević; Marinka Mravak Stipetić; Mirna Situm; Branka Marinović; Sven Seiwerth; Denis Baričević; Božana Lončar
Journal:  Wien Klin Wochenschr       Date:  2013-06-21       Impact factor: 1.704

Review 4.  Recent advances in the understanding of severe cutaneous adverse reactions.

Authors:  N R Adler; A K Aung; E N Ergen; J Trubiano; M S Y Goh; E J Phillips
Journal:  Br J Dermatol       Date:  2017-09-29       Impact factor: 9.302

5.  Testing for drug hypersensitivity syndromes.

Authors:  Craig M Rive; Jack Bourke; Elizabeth J Phillips
Journal:  Clin Biochem Rev       Date:  2013-02

6.  Influence of antidrug antibodies on plectasin efficacy and pharmacokinetics.

Authors:  Karoline Sidelmann Brinch; Niels Frimodt-Møller; Niels Høiby; Hans-Henrik Kristensen
Journal:  Antimicrob Agents Chemother       Date:  2009-08-17       Impact factor: 5.191

Review 7.  Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist.

Authors:  Marwan H Adwan
Journal:  Curr Rheumatol Rep       Date:  2017-01       Impact factor: 4.686

8.  Acute compartment syndrome of the forearm as a rare complication of toxic epidermal necrolysis: a case report.

Authors:  Tamer Kamal; Sherif Elnikety; Heba Mashaly; James Casha
Journal:  J Med Case Rep       Date:  2012-03-20

9.  Immunologic evaluation of drug allergy.

Authors:  Enrique Gómez; Maria Jose Torres; Cristobalina Mayorga; Miguel Blanca
Journal:  Allergy Asthma Immunol Res       Date:  2012-05-30       Impact factor: 5.764

10.  Purulent bullous epidermal necrolysis: A potential new clinical pattern of drug eruption.

Authors:  Lun-Fei Liu; Jian-Liang Yan; Jian-You Wang; Ji-Su Chen; Sui-Qing Cai; Li-Min Lao; Min Zheng
Journal:  Exp Ther Med       Date:  2013-02-01       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.